- 英文名称
- Tiotropium bromide hydrate
- 分子式
- C19H22BrNO4S2.H2O
- 分子量
- 490.43
- 中文别名
- (1R,2R,4S,5S,7S)-7-[2-羟基-2,2-二(2-噻吩基)乙酰氧]-9,9-二甲基-3-环氧-9-氮阳离子三环辛烷[3.3.1.02.4]壬烷溴化物一水合物; 泰乌托品; 噻托溴铵一水; 噻托溴铵; rel-(1R,2R,4S,5S,7s)-7-(2-羟基-2,2-二(噻吩-2-基)乙酰氧基)-9,9-二甲基-3-氧杂-9-氮杂三环[3,3,1,2,4]壬-9-溴化铵多水合物; (1R,2R,4S,5S,7S)-7-[2-HYDROXY-2,2-DI(2-THIENYL)ACETOXY]-9,9-DIMETHYL-3-OXA-9-AZONIATRICYCLO[3.3.1.02,4] NONANE BROMIDE MONOHYDRATE; TIOTROPIUM BROMIDE MONOHYDRATE; TIOTROPIUM BROMDIE; Tiotropium; (1a,2b,4b,5a,7b)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide hydrate; (1a,2b,4b,5a,7b)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide; Tiotropium Bromide; Tiotropium bromide xhydrate; 3-Oxa-9-azoniatricyclo[3.3.1.0]nonane, 7-[(2-hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-, bromide, (1R,2R,4S,5S)-, hydrate (1:1:1); 3-oxa-9-azoniatricyclo[3.3.1.0]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, bromide, (1R,2R,4S,5S)-, monohydrate; (1R,2R,4S,5S,7S)-7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane bromide hydrate; (1R,2R,4S,5S,7S)-7-{[Hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonanbromidhydrat; bromure de (1R,2R,4S,5S,7S)-7-{[hydroxy(dithiophén-2-yl)acétyl]oxy}-9,9-diméthyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane hydrate; (1R,2R,4S,5S,7s)-7-[2-Hydroxy(di-2-thienyl)acetoxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane bromide hydrate (1:1:1); Tiotropium (bromide hydrate); rel-(1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide xhydrate
- 用途
- 噻托溴铵一水合物是抗胆碱药，支气管扩张剂及毒蕈碱受体拮抗剂，在豚鼠和人气道中具有抗胆碱能神经引起的收缩作用，起效比atropine或ipratropium bromide慢，能抑制AM、MonoMac6和A549细胞释放趋化物质，抑制PBMC产生Th2型细胞因子，在急性和慢性哮喘小鼠模型中降低气道炎症和Th2型细胞因子产生，降低杯状细胞转化、气道平滑肌厚度和纤维化，减少过敏性哮喘豚鼠模型中气道平滑肌质量、肌球蛋白表达和收缩，在COPD豚鼠模型中废除LPS诱导的中性粒细胞、杯状细胞、胶原沉积和muscularised微血管增加（对肺气肿无影响）。
